
ΔΙΑΓΝΩΣΤΙΚΗ ΠΡΟΣΠΕΛΑΣΗ ΣΤΗΝ ΠΝΕΥΜΟΝΙΚΗ ΥΠΕΡΤΑΣΗ



Β. Σταματοπούλου

Ειδικευόμενη Πνευμονολογίας, PhDc Πνευμονολογική Κλινική ΠαΓΝΗ

Ξενοδοχείο Aquila Atlantis
 03,04 & 05.11.2023
 ΣΤΡΟΓΓΥΛΟ ΤΡΑΠΕΖΙ

Σι-μα Ιητηρ(ιατρός) Μινωϊκή Κρήτη

1ο ΠΟΛΥΘΕΜΑΤΙΚΟ ΣΥΝΕΔΡΙΟ

ΙΑΤΡΙΚΟΥ ΣΥΛΛΟΓΟΥ ΗΡΑΚΛΕΙΟΥ

Πνευμονική Εμβολή-Πνευμονική υπέρταση

Προεδρείο:

Μπούρος Δ. (Καθ. Πνευμονολογίας-Φυματιολογίας)

Τζανάκης Ν. (Καθ. Πνευμονολογίας-Φυματιολογίας)

- Κλινική εικόνα και αντιμετώπιση πνευμονικής εμβολής,
 Καραγιάννης Κ. (Πνευμονολόγος-Φυματιολόγος)
- Απεικόνιση στην πνευμονική εμβολή,
 Δετοράκης Ε. (Ακτινολόγος)
- Προφυλακτική αγωγή υποτροπής στην πνευμονική εμβολή,
 Λαμπίρη Ε. (Πνευμονολόγος-Φυματιολόγος)
- Διαγνωστική προσπέλαση στην Πνευμονική Υπέρταση,
 Σταματοπούλου Β. (Πνευμονολόγος-Φυματιολόγος)

 Διαταραχές αναπνοής κατά τον ύπνο και πνευμονική υπέρταση,
 Σχίζα Σ. (Καθ. Πνευμονολογίας-Φυματιολογίας)


Σχολιαστές: Καλογριδάκη Ε. (Γενικός Ιατρός)

> Πασπαράκη Ειρ, (Πνευμονολόγος-Φυματιολόγος)

DEFINITIONS

The definitions for PH are based on haemodynamic assessment by right heart catheterization (RHC)

PH is defined by a mean pulmonary arterial pressure (mPAP)>20 mmHg at rest



PH IN NUMBERS


Pulmonary hypertension is a <u>major global health issue</u>. All age groups are affected.

PH prevalence of 1% of the global population.

Due to the presence of cardiac and pulmonary causes of PH, prevalence is higher in individuals aged >65 years.


Globally, LHD is the leading cause of PH. Lung disease, especially COPD, is the second most common cause.

Irrespective of the underlying condition, developing PH is associated with worsening symptoms and <u>increased</u> <u>mortality</u>



²⁰²² ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3618–3731, https://doi.org/10.1093/eurheartj/ehac237 Rich, S., Haworth, S. G., Hassoun, P. M., & Yacoub, M. H. (2018). Pulmonary hypertension: the unaddressed global health burden. The Lancet Respiratory Medicine, 6(8), 577-579.


EPIDEMIOLOGY






- Incidence: 6 cases/million/year
- Young females
- Now diagnosed in pts ≥65, with CV comorbidities
- 50% of pts with HEFpEF
- 60–70% of pts with severe mitral valve disease
- 50% of pts with sympt. AoVS







- 1–5% of patients with advanced COPD+CRF
- IPF: 8–15% at initial work-up, 30-50% in advanced, 60% in endstage disease

• CTEPH incidence of 2–6 cases/million adults/year






STEP 1 \rightarrow SUSPICION



SYMPTOMS


- Patients with PH are likely to be seen by firstline physicians (general practitioners)
- Non-specific symptoms.
- Symptoms of RV dysfunction associated with exercise in the earlier course of the disease.
- The cardinal symptom is dyspnoea on progressively minor exertion.



CLINICAL EXAMINATION

 Comprehensive medical (including familial) history and thorough physical examination

 Importantly, the physical examination may also be the key to identifying the underlying cause of PH




ECG

- ✓ May raise suspicion of PH, deliver prognostic information, and detect arrhythmias/signs of LHD.
- ✓ In adults with clinical suspicion of PH, RAD has a high predictive value for PH.
- Normal ECG does not exclude the presence of PH
- Normal ECG + normal biomarkers (BNP/NTproBNP) = low likelihood of PH


Table 8Electrocardiogram abnormalities in patientswith pulmonary hypertension

Typical ECG abnormalities in PH⁶⁶

- P pulmonale (P >0.25 mV in lead II)
- Right or sagittal axis deviation (QRS axis >90° or indeterminable)
- RV hypertrophy (R/S >1, with R >0.5 mV in V1; R in V1 + S in lead V5 > 1 mV)
- Right bundle branch block—complete or incomplete (qR or rSR patterns in V1)
- RV strain pattern^a (ST depression/T-wave inversion in the right pre-cordial V1–4 and inferior II, III, aVF leads)
- Prolonged QTc interval (unspecific)^b



STEP 2 \rightarrow DETECTION



The second step includes classical, non-invasive lung and cardiac testing.

CHEST RADIOGRAPHY

Table 9Radiographic signs of pulmonary hyperten-
sion and concomitant abnormalities


Signs of PH and concomitant abnormalities	Signs of left heart disease/ pulmonary congestion	Signs of lung disease
Right heart enlargement	Central air space opacification	Flattening of diaphragm (COPD/ emphysema)
PA enlargement (including aneurysmal dilatation)	Interlobular septal thickening 'Kerley B' lines	Hyperlucency (COPD/ emphysema)
Pruning of the peripheral vessels	Pleural effusions	Lung volume loss (fibrotic lung disease)
'Water-bottle' shape of cardiac silhouette ^a	Left atrial enlargement (including splayed carina) Left ventricular dilation	Reticular opacification (fibrotic lung disease)

© ESC/ERS 2022

PFTs + ABGs



Arterial Blood Gas (ABG)



PFTs: REDUCED DLCO

IPAH: normal Va, restrictive pattern (20-50%) or normal, airway obstruction (20-40%) +/- small airways disease (ET-1 \rightarrow bronchoconstriction)

Group 2: restrictive pattern (reduced TLC/FVC)

Group 3:

- COPD: obstruction + elevated RV
- ILDs: reduced FVC + reduced TLC
- CPFE: elevated or normal FVC/RV/TLC + **disproportionate** reduced DLCO


Group 4: 20-30% restrictive pattern

<u>ABGs</u>

- normal/reduced PaO2
- reduced PaCO2


2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3618–3731, https://doi.org/10.1093/eurheartj/ehac237 Low, A. T., et al. "Lung function in pulmonary hypertension." Respiratory medicine 109.10 (2015): 1244-1249. TTE


- RV pressure overload and dysfunction, detected by TTE but insufficient to confirm a diagnosis of PH
- Valuable tool for detecting the cause of suspected or confirmed PH
- There is no single echocardiographic parameter that reliably informs about PH status and underlying aetiology



TTE

TRV(peak) = the key variable for assigning the echocardiographic probability of PH.







STEP 3 \rightarrow CONFIRMATION

<u>RHC</u>

- Gold standard for diagnosing and classifying PH
- Expertise and meticulous methodology following standardized protocols is required





HEMODYNAMIC DEFINITION






Table 6 Clinical hypertension	classification	of	pulmonary
GROUP 1 Pulmonary arte	rial hypertension (PA	(H)	
1.1 Idiopathic 1.2 Heritable ^a			
1.3 Associated with drug	gs and toxins ^a		
1.4 Associated with:			
1.4.1 Connective tiss	sue disease		
1.4.2 HIV infection			
1.4.3 Portal hyperter	nsion		
1.4.4 Congenital hea	rt disease		
1.4.5 Schistosomiasis	S		
1.5 PAH with features of	venous/capillary (PV	OD/PC	CH) involvement
GROUP 2 PH associated v	with left heart disease	9	
2.1 Heart failure:			
2.2 Valvular heart diseas	se		
GROUP 3 PH associated v	with lung diseases and	l/or hy	poxia
3.1 Obstructive lung dise	ease or emphysema		
3.2 Restrictive lung disea 3.4 Hypoventilation synd			
3.5 Hypoxia without lun GROUP 4 PH associated v			
4.1 Chronic thrombo-er	mbolic PH		
4.2 Other pulmonary ar	tery obstructions ^c		
GROUP 5 PH with unclear	r and/or multifactoria	al mech	anisms
5.1 Haematological disor	rders ^d		
5.2 Systemic disorders ^e			
5.3 Metabolic disorders ^f			

SCREENING

Despite the advent of PAH therapies that prevent clinical worsening and effective interventions for CTEPH, the time from symptom onset to PH diagnosis remains at >2 years with most patients presenting with advanced disease



TAKE HOME MESSAGES



- 1. New onset exertional dyspnea \rightarrow **SUSPECT** of PH
- 2. Assess probable lung or cardiac disease and <u>DETECT</u> the probable cause
- 3. If PH probability is high, <u>CONFIRM</u> by RHC or <u>REFER</u> the patient to a PH center.

PULMONARY HYPERTENSION AWARENESS MONTH

NOVEMBER

ΕΥΧΑΡΙΣΤΩ ΓΙΑ ΤΗΝ ΠΡΟΣΟΧΗ ΣΑΣ!